"Disease Progression" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
| Descriptor ID |
D018450
|
| MeSH Number(s) |
C23.550.291.656
|
| Concept/Terms |
Disease Progression- Disease Progression
- Disease Progressions
- Progression, Disease
- Progressions, Disease
|
Below are MeSH descriptors whose meaning is more general than "Disease Progression".
Below are MeSH descriptors whose meaning is more specific than "Disease Progression".
This graph shows the total number of publications written about "Disease Progression" by people in this website by year, and whether "Disease Progression" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 4 | 4 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 6 | 6 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 7 | 7 |
| 2010 | 0 | 8 | 8 |
| 2011 | 1 | 7 | 8 |
| 2012 | 1 | 9 | 10 |
| 2013 | 1 | 14 | 15 |
| 2014 | 0 | 14 | 14 |
| 2015 | 0 | 25 | 25 |
| 2016 | 2 | 17 | 19 |
| 2017 | 0 | 11 | 11 |
| 2018 | 0 | 8 | 8 |
| 2019 | 1 | 10 | 11 |
| 2020 | 2 | 14 | 16 |
| 2021 | 2 | 6 | 8 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 2 | 3 |
| 2025 | 0 | 6 | 6 |
| 2026 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Disease Progression" by people in Profiles.
-
Independent association between acute kidney injury and kidney function trajectory. Kidney Int. 2026 Jul; 110(1):206-213.
-
Proactive Engagement of Patients With Advanced Chronic Kidney Disease to Reduce Clinical Complications: The Kaiser Permanente Northern California Experience. Perm J. 2026 06 15; 30(2):20-29.
-
Antiviral treatment and statin use and risk of decompensated cirrhosis in patients with hepatitis C: a time-dependent analysis of a retrospective cohort study. BMJ Open Gastroenterol. 2026 Mar 27; 13(1).
-
De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy. Mult Scler. 2026 Apr; 32(4):409-420.
-
Clinical risk prediction models for worsening heart failure events and all-cause mortality in adults with mild-to-moderate chronic kidney disease. ESC Heart Fail. 2026 Feb 03; 13(1).
-
Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis. Neurology. 2026 Jan 27; 106(2):e214473.
-
Optimizing Proteinuria Evaluation and Management after Acute Kidney Injury: Insights from the Chronic Renal Insufficiency Cohort Study. Kidney360. 2026 Mar 01; 7(3):527-534.
-
Effect of eosinophilia on duration of hospital stay in patients admitted with acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2025 Nov-Dec; 249:108467.
-
Assessment of adherence to guidelines for biochemical monitoring and ursodeoxycholic acid treatment response in a retrospective cohort of US patients with primary biliary cholangitis. BMJ Open Gastroenterol. 2025 Oct 22; 12(1).
-
Worsening heart failure events in adults with mild-to-moderate chronic kidney disease. Am Heart J. 2026 Feb; 292:107290.